Bevarest 400mg/16ml & 100mg/4ml

Category: Monoclonal antibody or Anti-angiogenesis drug Bevacizumab is sold under the brand name Bevarest which belongs to vascular endothelial growth factor directed antibody, the main ingredient which is used as bevacizumab. Bevarest consist of human framework regions and murine complementarity-determining regions. Bevarest is a combined human monoclonal antibody IgG1, that predicament to and prohibits the biological activity of human vascular endothelial growth factor (VEGF)

INDICATION

Bevarest is indicated for the treatment :
• In combination with 5-fluorouracil chemotherapy administered intravenously, first or second line drug of choice for Metastatic colon or rectal cancer
• Concurrent use with carboplatin and paclitaxel as first line therapy for Non-squamous, non-small cell lung cancer
• Used in the treatment of recurrent Glioblastoma in adults
• Concurrent use with interferon alfa for Metastatic renal cell cancer
• Concurrent use with paclitaxel & cisplatin or paclitaxel & topotecan for Metastatic cervical cancer
• In combination with paclitaxel, pegylated liposomal doxorubicin or topotecan for Epithelial ovarian, fallopian tube or peritoneal cancer.

Key point :

Avoid administrating Bevarest before at least 28 days following surgery and the wound is completely cured

Metastatic colorectal carcinoma :

The Bevarest usual dosage by concomitant with 5-fluorouracil based chemotherapy. Bevarest 5mg/kg for every 2 weeks IV in concomitant with bolus IFL Bevarest 10mg/kg for every 2 weeks IV in combination with FOLFOX4 Bevarest 5mg/kg IV for every 2 weeks or Bevarest 7.5 mg/kg as IV every 3 weeks by concurrently take with fluoropyrimidine Irinotecan or fluoropyrimidine oxaliplatin based therapy

Non-small cell lung cancer :

The patients regular dosage of Bevarest is 15mg/kg IV for every 3 weeks by interacting with carboplatin and paclitaxel

Glioblastoma :

Bevarest 10mg/kg administered IV for every 2 weeks

Metastatic renal cell cancer :

Concurrent use with interferon alfa:  The usual dose of Bevarest is 10mg/kg IV for every 2 weeks

Metastatic cervical cancer :
The usual dose of Bevarest; Bevarest 15mg/kg given intravenously for every 3 weeks by combining with paclitaxel and cisplatin or with paclitaxel and topotecan
Epithelial ovarian, fallopian tube or peritoneal cancer :
The usual dose of Bevarest for Platinum opposing:; 10mg/kg of Bevarest for every 2 weeks by concurrent use with paclitaxel, pegylated liposomal doxorubicin or topotecan Or The regular dosage of Bevarest; 15mg/kg of Bevarest given through IV for every 3 weeks by combining with topotecan The usual dose of Bevarest for Platinum responsive; 15mg/kg given IV for 3 weeks in concomitant with carboplatin and paclitaxel for 6 to 8 cycles The recommended dosage of Bevarest; 15mg/kg of Bevarest given IV for 3 weeks by combining with gemcitabine & carboplatin for 6 to 10 cycles.

PHARMACOKINETICS:

The pharmacokinetic form of Bevarest is assayed by measuring total serum Bevacizumab concentration.
Distribution:
The volume of distribution is 2.9 (22%) L
Elimination:
The terminal half life period of Bevacizumab is 20days (11 to 50days)

MECHANISM:

Bevarest constitute an active ingredient like Bevacizumab which joined to VEGF and will not have communication of VEGF to its receptors like Flt-1 & KDR that present on the surface of the cells. While this interaction inhibits endothelial cell proliferation and new blood vessel production occurs Hence in counts discontinuation of metastatic tumor cells growth happens.
STORAGE

Bevarest vial should be stored at 2 to 8℃ (36 to 46℉) Single use vial Discard the left out medicine under guidance of pharmacist

PRECAUTION:

Caution with use in the conditions like;
Previously If you have taking or ever had DPD (dihydropyrimidine dehydrogenase) deficiency of enzyme . Inform the doctor about this then your doctor may preferably inform you avoid taking Bevarest. Discuss with the doctor that you have or have ever had renal, hepatic, or cardiac problem Discuss with the doctor that are you pregnant or plan to become pregnant. Avoid planning to have children while on treatment with Bevarest. You should use a essential method of conceiving to prevent pregnancy in yourself or your partner during your treatment with Bevarest. The drug will harm the fetus. Avoid breast feeding while on treatment with Bevarest While using Bevarest these are some other complications occurred during therapy, care should be taken Hypertension Posterior reversible encephalopathy syndrome Gastrointestinal perforations Wound healing complications Hemorrhage Arterial thromboembolic events Venous thromboembolic events Embryo fetal toxicity occurs.

DRUG INTERACTION:

If you missed a dose take it as soon as possible, if time reach for next dose, While interaction of Bevarest with paclitaxel & Carboplatin, leads to lowering in exposure of paclitaxel after four cycles of therapy. Interaction of Bevarest with paclitaxel & Carboplatin leads to increase the paclitaxel exposure at day 6

MISSED DOSE:

If patient fail to take the dose or missed the cycle means must consult with oncologist and follow the regular dosing schedule Do not take overdose

SIDE EFFECTS:

Gastrointestinal perforation and fistulae
Surgery and wound healing complication
Hemorrhage
Arterial thromboembolic events
Venous thromboembolic events
Hypertension
Posterior reversible encephalopathy syndrome
Renal injury & Proteinuria
Infusion reactions
Ovarian failure
Congestive heart failure
Neutropenia, mucosal inflammation, infection, neuropathy, Epistaxis, erythrodysaesthesia.

Address:

Apartment No.304 A Wing,
Shiva Sakthi chs lts,
JP Road, Near Apna Bazar,
Andheri(West),
Mumbai - 400058
Maharashtra.

Phone Number:

+91-9987711567

Mail-id: 

applepharamaceutical@gmail.com

Lenalidomide - Lenangio 10mg tablet online | Myapplepharma

Lenangio 10mg 

Lenangio 10mg is belongs to anticancer medication which contains Lenalidomide as an active substance which belongs to thalidomide analogue.
Lenangio 10mg is used to the disease condition by combining with dexamethasone.
Lenangio 10mg tablets  consist of some other pharmacological activities like immuno modulatory & anti-angiogenesis.
Lenangio 10mg is a prescription drug that can only use under the supervision of medical oncologist.

Lenangio 10mg

INDICATION

The indications of Lenangio 10mg are;
Lenangio combination with dexamethasone is indicated to treat the patients suffered from multiple myeloma
Lenangio is indicated for the patients having transfusion-dependent anemia because of intermediate 1 risk myelodysplastic syndrome along with deletion 5q cytogenetic abnormality without or without addition cytogenetic abnormalities
Lenangio is used to treat the patients with mantle cell lymphoma in which its used whose the disease was relapsed or progressed after two before treatment, especially the disease not response with the bortezomib therapy.


The adult usual dose of Lenangio 10mg tablets in myelodysplastic syndromes is 10mg and administrated once a day.
For renal damaged patients;
CrCl >60ml/min In Patients should not needed dosage adjustment of Lenangio
CrCl 30 to 60ml/min In Patients, 5mg of Lenangio should administer orally as once daily
CrCl <30ml/min In Patient, 2.5mg of Lenangio should be given orally as a once daily.
Dosage variation;

Thrombocytopenia:

Drops to <50000/mcL, treatment should be interrupted. Back to > or equal to 50000/mcL, follow the Lenangio of 5mg per day.
Neutropenia;
Drops to <500/mcL, treatment should be delayed. Back to > or equal to 500/mcL, treatment should be follow to 5mg per day.
Multiple myeloma;
In this disease, concomitant use of dexamethasone with Lenangio. The regular dose of Lenangio is 25mg should be given as once in a day on day 1 to 21.
The dose of dexamethasone;
Dexamethasone 40mg should be continued on day 1 to 4, 9 to 12 & 17 to 20 of each period of 28-day cycles. Patient with greater than 75 years, dexamethasone 20mg should be prescribed on day 1, 8, 15, & 22.
Mantle cell lymphoma;
The usual dose of Lenangio for this disease is 25mg should be given orally as once daily.
For renal damaged patients;
CrCl 30 to 60ml/min in patient, Lenangio 10mg should be given as once daily. CrCl <30ml/min in patients, Lenangio 15mg tablets should be used for q48hr.
Pediatrics;
The safety & efficiency of Lenalidomide has not been described in pediatric patients with age of <18 years.

MECHANISM

Lenangio 10mg involves in the prudence of tumor and factor alpha arrangement, that reinforcement the T-cells and leads to lessening plasma levels of cytokines vascular endothelial growth factor and fundamental fibroblast growth factor.
Lenangio 10mg tablets  is moreover engaged with the stave off angiogenesis.
Lenalidomide is furthermore authorize G1 cell cycle capture and apoptosis of ruinous cells.

PHARMACOKINETICS

Absorption:
Absorbed rapidly with peak plasma concentration is between 0.625 and 1.5 hrs. combining with food will not change the prolong of absorption but dose decrease in Cmax.
Distribution:
Bounding of plasma protein is 30%
Metabolism:
Mainly metabolized in two metabolites is hydroxy-lenalidomide and N-acetyl-lenalidomide.
Excretion:
Primarily eliminated in renal route and the dose excreted via urine 90% and feces 4% and half-life is 3hrs

DRUG INTERACTION

Interaction of Lenangio 10mg with digoxin leads to increased concentration of digoxin causes increased risk of adverse effects related to digoxin.
Interaction of Lenangio 10mg tablets  with Erythropoietic agents, cause to produced rises in risk of thrombosis. Discuss with the patients prior to starting this combination treatment.
Interaction of Lenangio 10mg tablets  with warfarin, will produce increased exposure of hemorrhage disorders. check the INR value & prothrombin time.

CONTRAINDICATION

When pregnancy period the drug is contraindicated The patients are contraindicated to hypersensitivity reaction and the Lenangio 10mg component.
OVER DOSAGE

Over dosage of Lenangio 10mg tablets  will cause neutropenia & thrombocytopenia as mainly common side effects. Give the patient general supportive treatment. check the blood cells counts regularly during the treatment.

MISSED DOSE

The missed dose of Lenangio 10mg should be avoided. If missed dose founded, then patients should be consulting with doctor specialized in oncologist Regulate the usual dosing schedule.

SIDE EFFECTS

Second primary malignancies Hepatotoxicity , Hypersensitivity reactions, Thyroid dysfunction, Fetal toxicity, Hematological toxicity, Tumor lysis syndrome, Tumor flare reactions, Increase of mortality rate.
Common side effects;
Diabetes mellitus, Rash, Insomnia, Depression, Deep vein thrombosis, Myocardial infraction, Renal failure, Squamous cell carcinoma, Basal cell carcinoma, Fatigue, Asthenia, Pyrexia, Pain, Diarrhea, Dyspepsia, Bone pain, Neck pain, Respiratory infections, UTI, Influenza, Sepsis, Headache, Anemia, Loss of appetite, Hypokalemia, Hyperglycemia, Hypocalcaemia, Dehydration, Gout.

WARNING

The some of the common life-threatening condition like :
Venous & arterial thromboembolism
Blood clotting effects
Embryo fetal damage
Hypersensitivity reactions
Hematological disorders
For all these conditions, some supportive measures should be used and provide safety measures.

Contact us :

Address :

Apartment No.304 A Wing,

Shiva Shakthi chs ltd,

JP Road, Near Apna Bazar,

Andheri(west),

Mumbai - 40058.

Maharashtra.

Phone Number :

+91-9987711567

Email ID :

applepharamaceutical@gmail.com